Anavex Life Sciences Corp. (AVXL) — 10-K Filings
All 10-K filings from Anavex Life Sciences Corp.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Anavex Faces EMA Setback on Alzheimer's Drug Blarcamesine
— Nov 25, 2025 Risk: high
ANAVEX LIFE SCIENCES CORP. (AVXL) is a clinical-stage biopharmaceutical company focused on CNS diseases. For the fiscal year ended September 30, 2025, the compa -
Anavex Life Sciences Files 2024 10-K
— Dec 23, 2024 Risk: medium
Anavex Life Sciences Corp. filed its 10-K for the fiscal year ending September 30, 2024, reporting on its progress in developing treatments for neurodegenerativ
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX